^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

BIOMARKER IDENTIFICATION IN RELAPSED/REFRACTORY NON-GERMINAL CENTER B-CELL–LIKE DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH ZANUBRUTINIB

Published date:
06/27/2020
Excerpt:
For the 56 non-GCB patients with HTG gene expression profiles, PAX5 expression was significantly higher in monotherapy responders, and PIM1, BCL2, and FOXP1 expression was higher in combination therapy responders.